局部晚期鼻咽癌TP方案诱导化疗及同期放化疗初步观察  

Preliminary Research of TP-based Induction Chemotherapy and Concurrent Chemotherapy in the Treatment of Locally Advanced NPC

作　　者：李金伟 肖海[2] 王蓉[2] 曾红学 

机构地区：[1]江西省赣州市肿瘤医院,江西赣州341000 [2]赣南医学院

出　　处：《中国医学创新》2016年第27期10-13,共4页Medical Innovation of China

基　　金：赣州市科技局科技计划项目(赣市科发【2012】36号-194)

摘　　要：目的：观察局部晚期鼻咽癌诱导化疗及不同化疗方案的依从性及不良反应。方法：将60例局部晚期鼻咽癌患者按照随机数字表法分为A、B、C三组,A组TP诱导化疗＋同期顺铂放化疗,B组顺铂同期放化疗,C组TP同期放化疗。放疗为调强放疗,GTVnx 68~72 Gy,GTVnd 65~70 Gy。观察三组治疗依从性及不良反应情况。结果：三组完成化疗数比例分别为80.0%、95.0%、90.0%,放疗全部足量完成,依从性均好,最常见反应为胃肠道反应、口咽黏膜炎、骨髓抑制、皮肤损伤,三组比较差异均无统计学意义（P〉0.05）。但同时中重度不良反应发生率A组最高,B组最低,差异有统计学意义（P〈0.05）。结论：局部晚期鼻咽癌诱导化疗后同期放化疗及顺铂同期放化疗、TP同期放化疗依从性均良好,前者同时中重度不良反应发生率较高,顺铂同期放化疗最轻。Objective： To observe the adherence and adverse reactions of induction chemotherapy and different concurrent chemotherapy regimens for locally advanced nasopharyngeal carcinoma （ NPC ） . Method： A total of 60 patients with locally advanced NPC were randomly divided into A, B, C groups, 20 cases in each group.Group A was given TP-based induction chemotherapy, followed by concurrent chemoradiotherapy with cisplatin; Group B was given Cisplatin-based concurrent chemoradiotherapy.Group C was given TP-based concurrent radiochemotherapy.Radiotherapy was used by IMRT, GTVnx 68-72 Gy, GTVnd 65-70 Gy.The treatment compliance and incidence of adverse reactions of three groups were observed.Result： Group A, B and C completed the expected number of chemotherapy rates were 80.0%, 95.0%, 90.0%.Radiotherapy were completed at sufficient amount, compliance was good, the most common were gastrointestinal, oropharyngeal mucositis, myelosuppression, skin damage.In severe injuries differences were no statistical difference （ P〉0.05 ） .But all adverse reactions rates were statistically different, group A was the highest, group B was the lowest, there was statistical significance （P〈0.05） .Conclusion： Locally advanced NPC treated by TP-based induction chemotherapy followed by cisplatin-based concurrent chemoradiotherapy, cisplatin-based concurrent radiochemotherapy, TP-based concurrent chemoradiotherapy, the compliance of treatment are good.The moderate and severe adverse reactions of the former is highest, cisplatin-based concurrent chemotherapy is lightest.

关 键 词：局部晚期鼻咽癌 同期放化疗 诱导化疗 不良反应 

分 类 号：R739.63[医药卫生—肿瘤]